Top-Rated StocksTop-RatedNASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis → why 99.94% won’t make you money (From Prosper Trading Academy) (Ad) Free IOVA Stock Alerts $8.08 -0.08 (-0.98%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$7.87▼$8.1650-Day Range$7.78▼$13.9852-Week Range$3.21▼$18.33Volume5.78 million shsAverage Volume7.89 million shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice Target$24.64 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Iovance Biotherapeutics alerts: Email Address Iovance Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside204.9% Upside$24.64 Price TargetShort InterestBearish22.34% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment1.40Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.35) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.30 out of 5 starsMedical Sector125th out of 913 stocksBiological Products, Except Diagnostic Industry12th out of 152 stocks 3.5 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIovance Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Iovance Biotherapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted22.34% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Iovance Biotherapeutics has recently decreased by 2.44%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIovance Biotherapeutics has received a 70.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Iovance Biotherapeutics is -0.82. Previous Next 4.1 News and Social Media Coverage News SentimentIovance Biotherapeutics has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Iovance Biotherapeutics this week, compared to 6 articles on an average week.Search Interest68 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.MarketBeat Follows43 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 39% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iovance Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.35) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Iovance Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsWill this AI Micro-Cap be Bigger than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout AI stock. But right now... There's only ONE AI stock you should be watching.Get the full story here >>> About Iovance Biotherapeutics Stock (NASDAQ:IOVA)Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Read More IOVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOVA Stock News HeadlinesJune 16 at 3:30 AM | americanbankingnews.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Buy" by BrokeragesMay 29, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)May 29, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals Inc (AMLX) and Vaxcyte (PCVX)May 24, 2024 | msn.comWhat's Going On With Iovance Biotherapeutics Today?May 24, 2024 | globenewswire.comIovance Biotherapeutics to Present at Upcoming Conferences and EventsMay 23, 2024 | globenewswire.comIovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual MeetingMay 22, 2024 | fool.comBull Market Buys: 2 Growth Stocks to Own for the Long RunMay 17, 2024 | globenewswire.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 16, 2024 | fool.com4 Small-Cap Value Stocks That Could Go ParabolicMay 13, 2024 | benzinga.comLooking At Iovance Biotherapeutics's Recent Unusual Options ActivityMay 13, 2024 | seekingalpha.comIovance Biotherapeutics' Amtagvi: Innovative Therapy, Financial Strain (Rating Downgrade)May 11, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in May 2024May 11, 2024 | markets.businessinsider.comIovance Biotherapeutics Poised for Growth: Analyst Reiterates Buy Rating Amid Strong Q1 Performance and Promising Clinical AdvancementsMay 11, 2024 | fool.comIovance Biotherapeutics Reports a Q1 Revenue MissMay 11, 2024 | msn.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call TranscriptMay 11, 2024 | finance.yahoo.comIovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ...May 10, 2024 | benzinga.comIovance Biotherapeutics's Options: A Look at What the Big Money is ThinkingMay 10, 2024 | seekingalpha.comIovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On AmtagviMay 10, 2024 | fool.comWhy Iovance Stock Is Down 18% TodayMay 10, 2024 | markets.businessinsider.comIovance Biotherapeutics: A Strong Buy on Robust Growth Potential and Early Launch SuccessMay 9, 2024 | investorplace.comIOVA Stock Earnings: Iovance Biotherapeutics Meets EPS, Misses Revenue for Q1 2024May 9, 2024 | sfgate.comIovance Biotherapeutics: Q1 Earnings SnapshotMay 9, 2024 | finance.yahoo.comIovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 9, 2024 | globenewswire.comIovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 5, 2024 | fool.comGot $500? These Hot Growth Stocks Are Screaming Buys Right NowSee More Headlines Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/17/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees557Year Founded2013Price Target and Rating Average Stock Price Target$24.64 High Stock Price Target$34.00 Low Stock Price Target$17.00 Potential Upside/Downside+206.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-444,040,000.00 Net Margins-23,615.70% Pretax Margin-23,872.37% Return on Equity-71.45% Return on Assets-55.17% Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.42 Sales & Book Value Annual Sales$1.19 million Price / Sales1,888.26 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book3.52Miscellaneous Outstanding Shares279,830,000Free Float250,730,000Market Cap$2.25 billion OptionableOptionable Beta0.81 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Frederick G. Vogt Esq. (Age 50)J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary Comp: $1.39MMr. Jean-Marc Bellemin M.B.A. (Age 51)CFO, Principal Accounting Officer & Treasurer Comp: $932.2kDr. Igor P. Bilinsky (Age 51)Chief Operating Officer Comp: $932.2kDr. Friedrich Graf Finckenstein M.D. (Age 57)Chief Medical Officer Comp: $1.06MMs. Sara PellegrinoVice President of Investor Relations & Public RelationsMs. Tracy WintonSenior Vice President of Human ResourcesMr. Howard B. Johnson M.B.A. (Age 64)Chief Business Officer Mr. James Ziegler M.B.A.Executive Vice President of CommercialDr. Raj K. Puri M.D.Ph.D., Executive VP of Regulatory Strategy & Translational MedicineMr. Brian Shew M.B.A.Senior VP & Head of Digital and Information TechnologyMore ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATENektar TherapeuticsNASDAQ:NKTRChina Biologic ProductsNASDAQ:CBPOVaxcyteNASDAQ:PCVXRepligenNASDAQ:RGENView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCSold 536,000 shares on 5/24/2024Ownership: 0.009%Zimmer Partners LPSold 451,500 shares on 5/17/2024Ownership: 0.016%Walleye Trading LLCBought 25,500 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 39,897 shares on 5/16/2024Ownership: 0.070%Jane Street Group LLCSold 91,100 shares on 5/16/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions IOVA Stock Analysis - Frequently Asked Questions Should I buy or sell Iovance Biotherapeutics stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOVA shares. View IOVA analyst ratings or view top-rated stocks. What is Iovance Biotherapeutics' stock price target for 2024? 10 brokerages have issued 1-year price objectives for Iovance Biotherapeutics' shares. Their IOVA share price targets range from $17.00 to $34.00. On average, they expect the company's stock price to reach $24.64 in the next twelve months. This suggests a possible upside of 204.9% from the stock's current price. View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts. How have IOVA shares performed in 2024? Iovance Biotherapeutics' stock was trading at $8.13 at the start of the year. Since then, IOVA stock has decreased by 0.6% and is now trading at $8.08. View the best growth stocks for 2024 here. When is Iovance Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our IOVA earnings forecast. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.03. The biotechnology company had revenue of $0.72 million for the quarter, compared to the consensus estimate of $1.99 million. Iovance Biotherapeutics had a negative net margin of 23,615.70% and a negative trailing twelve-month return on equity of 71.45%. Iovance Biotherapeutics's revenue for the quarter was up 71400.0% on a year-over-year basis. During the same period last year, the firm posted ($0.50) EPS. What ETFs hold Iovance Biotherapeutics' stock? ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Harbor Disruptive Innovation ETF (INNO).Alger Mid Cap 40 ETF (FRTY). What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), Xtrackers California Municipal Bond ETF (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX). Who are Iovance Biotherapeutics' major shareholders? Iovance Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.90%), Avoro Capital Advisors LLC (4.18%), Price T Rowe Associates Inc. MD (1.88%), Hood River Capital Management LLC (0.94%), Principal Financial Group Inc. (0.72%) and Rice Hall James & Associates LLC (0.61%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IOVA) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.